Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Eye (Lond) ; 30(5): 698-704, 2016 05.
Artigo em Inglês | MEDLINE | ID: mdl-26915744

RESUMO

PurposeTo determine the opinions from a patient perspective on relevant variables in the delivery of treatment for neovascular age-related macular degeneration (nAMD).MethodsPilot interviews with patients and doctors were conducted to identify what variables in the provision of a nAMD service were important. This led to the generation of two sets of scenario options. Subsequently 100 patients undergoing active treatment for nAMD in the National Health Service University Hospital, United Kingdom underwent interview assessment. They were asked to rank their preferences for provision of their care with reference to these two sets of scenario options. Using conjoint analysis, percentage preferences, and utility scores for each variable in each scenario design were calculated.ResultsNinety-five patients completed the preference ranking for both scenarios. Eight patients ranked worse vision as preferable to better vision and were excluded on the basis that they had not understood the task. The results of the remaining 87 patients are presented. The most important factor to patients was having good vision, followed by a one-stop service and less frequent follow up. The least important factors were label status of the drug, cost to the health service, and grade of the injector.ConclusionPatients regard good vision and minimal visits to the hospital above the status of injector, label status of drug, or cost to the NHS.


Assuntos
Inibidores da Angiogênese/uso terapêutico , Atenção à Saúde/estatística & dados numéricos , Preferência do Paciente/estatística & dados numéricos , Transtornos da Visão/tratamento farmacológico , Degeneração Macular Exsudativa/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Assistência Ambulatorial , Bevacizumab/uso terapêutico , Gerenciamento Clínico , Feminino , Custos de Cuidados de Saúde , Humanos , Injeções Intravítreas , Masculino , Ranibizumab/uso terapêutico , Medicina Estatal , Tempo para o Tratamento , Reino Unido , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Transtornos da Visão/fisiopatologia , Listas de Espera , Degeneração Macular Exsudativa/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA